Stock Hero Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Mocha Jet, Drugdoctor, RizZo, lasers, John_Langston, IB_
Search This Board:
Last Post: 4/25/2015 10:21:51 AM - Followers: 666 - Board type: Free - Posts Today: 3

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Feb 17, 2015
Elite Pharmaceuticals Provides Guidance On Phase III Study For ELI-200

Jan, 15 2015
Elite Pharmaceuticals Announces First Shipment Of Generic Isradipine Capsules

Dec, 16 2014
Elite Pharmaceuticals Awarded Second Canadian Patent For Abuse Deterrent Drug Formulation

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:

Third Quarter ending December 31, 2014
♦  Consolidated revenues for the third quarter of Fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of Fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Development of our proprietary abuse-deterrent opioid technology continues to be Elite's top priority. During the quarter, Elite invested an additional $2.3 million in clinical trials and other product development activities.

Highlights for the third quarter
♦  As of December 31, our working capital was $8.9 million, including cash of $8.3 million.
♦  Isradipine was recently launched, and we expect to introduce Hydroxyzine and Dantrolene in the near-term.
♦  We're a penny stock company with eyes on NASDAQ; we need to be Sarbanes Oxley compliant. So we are evaluating the gaps that we have by hiring consultants and external consultants in order to evaluate the checks and      balances we have in order for us to get there.
♦  We are creating infrastructure in our facilities with expanding the facilities and adding new equipment and upgrading the current equipment in order to support our (Eli-200) product launch.
2014 was our best year, 2015 will be the year we file our first ART product, and Q1 2016 will be the year we launch our first ART product and hopefully will be the year we will be on NASDAQ.

Nine-Month Period Ending December 31, 2014
♦  Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite's generic product lines.
♦  During the first nine months of the fiscal year, Elite has invested a total of $9.9 million in product development, including successful completion of the human abuse liability study for ELI-200.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Statement of Changes in Beneficial Ownership (4) 04/16/2015 07:28:52 PM
ELTP News: Annual Statement of Changes in Beneficial Ownership (5) 04/09/2015 01:55:05 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 04/08/2015 11:23:19 AM
ELTP News: Confidential Treatment Order (ct Order) 04/07/2015 02:40:06 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 03/09/2015 04:32:13 PM
#152018  Sticky Note The analysts you mention are confirming what seems no2koolaid 04/22/15 04:16:11 PM
#148487  Sticky Note Ya-don't-say???-Trial-record-1 of-66-for:-eli-200 Drugdoctor 03/21/15 11:04:27 AM
#142585  Sticky Note Great info! This is the beginning of a Dr Speculator Ninja 01/29/15 02:56:03 PM
#142438  Sticky Note FOR THOSE WANTING A DEEPER UNDERSTANDING OF WHY Couch 01/28/15 07:17:31 PM
#106205  Sticky Note Elite’s 1st Generation Triple Patents and their Purpose lasers 04/30/14 08:50:54 AM
#152236   anyone thinking of putting up a big wall csuck555 04/25/15 10:21:51 AM
#152235   just a micro bull trap Jimmy Joe 04/25/15 01:45:38 AM
#152234 SCHH 04/25/15 12:55:02 AM
#152233   That is not needed!!! John_Langston 04/24/15 09:27:13 PM
#152232   ELTP is where the early retirees are John_Langston 04/24/15 09:25:26 PM
#152231   Never seen ya on th MJ boards. NASDAQ2020 04/24/15 09:13:39 PM
#152229   Better yet; medical marijuana is the new craze John_Langston 04/24/15 08:44:03 PM
#152228   At least it is a phase 3 trial!!! John_Langston 04/24/15 08:36:08 PM
#152227   No just a micro bull trap to let John_Langston 04/24/15 08:32:45 PM
#152226   Maybe someone knows something about next week. NASDAQ2020 04/24/15 07:57:05 PM
#152225   Nice Buying rush in last thirty minutes John_Langston 04/24/15 07:38:18 PM
#152224   Yep just as soon as elite starts developing dr_lowenstein 04/24/15 07:27:40 PM
#152223   I did not happen!!! John_Langston 04/24/15 07:24:52 PM
#152222   That did not show on the time & John_Langston 04/24/15 07:24:06 PM
#152220   sweet! hoping it was one buyer! so 600k shares snupoled 04/24/15 06:21:05 PM
#152219   Nice Buying rush in last thirty minutes conix 04/24/15 06:11:15 PM
#152215   Manchin is out of his freaking mind toofun 04/24/15 05:38:22 PM
#152214   ELTP ADT opioids that doctors can feel safe Couch 04/24/15 05:26:46 PM
#152213   Hi Jim: 'the doji represent market uncertainty'...The sharpei 04/24/15 05:12:14 PM
#152212   Mr. C: I left out part of sharpei 04/24/15 05:01:31 PM
#152211   Not a chartist so could you please explain jimneutron 04/24/15 04:55:59 PM
#152210   Yes, but it is a shame that they dr_lowenstein 04/24/15 04:51:39 PM
#152209   Tingle! Would Elite be required to acquire Aqua 04/24/15 04:51:36 PM
#152208   ELTP Four Month Daily Chart for April... Today's sharpei 04/24/15 04:21:33 PM
#152206   No. mrwrn2010 04/24/15 04:17:42 PM
#152205   $ELTP P3 Blood and Urine Analyses. A very lasers 04/24/15 04:07:55 PM
#152204   Who want's to be out over the weekend? hondobud 04/24/15 04:06:27 PM
#152203   Blood and Urine analyses are very valuable information lasers 04/24/15 03:50:14 PM
#152201   600,000 BUY. Just clicked in. Dr Speculator Ninja 04/24/15 03:32:22 PM
#152200   quicker FDA approval for $ELTP's other Agonists NASDAQ2020 04/24/15 03:18:11 PM
#152199   Nasrat has his eyes on the NASDAQ for NASDAQ2020 04/24/15 03:12:18 PM
#152198   Gee Man WOW the PPS is lower now Couch 04/24/15 02:34:12 PM
#152197   If we only knew who was responsible for Gman24 04/24/15 02:13:34 PM
#152196   pps is absolutely horrendous. i keep hearing on csuck555 04/24/15 02:06:00 PM
#152195   Quick answer... BIG PHARMA ...$$$$$$$$$$$$$$$$$$$$$$$$..!!!!!! Gman24 04/24/15 02:00:19 PM
#152194   Now you're talking. Why this has not been tenor15824 04/24/15 01:57:32 PM
#152193   Don't forget Elite has ELI-154 24hr ER waiting NASDAQ2020 04/24/15 01:51:21 PM
#152192   All you can really do is to continue Gman24 04/24/15 01:49:44 PM
#152191   Yes, and obviously the FDA has an agenda tenor15824 04/24/15 01:42:04 PM
#152190   The same concern would be the potential of lasers 04/24/15 01:12:57 PM
#152189   The other Phase III specifically describes naltrexone pharmacokinetics. WeeZuhl 04/24/15 01:01:17 PM
#152188   $ELTP P3 Blood and Urine Analyses. A very lasers 04/24/15 12:49:47 PM
#152187   Hey I wonder who is SHORTing the stock Couch 04/24/15 12:48:15 PM
#152185   still NO proof offered. dr_lowenstein 04/24/15 12:38:33 PM
#152184   Blood and Urine analyses will have all of lasers 04/24/15 12:37:18 PM
#152183   LOL yes, those are routine SAFETY tests, where dr_lowenstein 04/24/15 12:24:33 PM
#152182   Secondary Outcome Measures: lasers 04/24/15 12:22:21 PM
#152181   More on Isradipine sharkey1 04/24/15 12:02:12 PM
#152180   Like they say --"It is what it is". conix 04/24/15 12:01:06 PM
#152179   Nasrat Hakim and $ELTP have done everything that lasers 04/24/15 11:56:55 AM